Thus, our study elucidates the clinical value of SEMA5B in KIRC, complements the results of previous studies (Hirota et al., 2006; Kundu et al., 2020), and provides a different perspective on how SEMA5B affects cancer progression and metastasis as well as provides insights for improving cancer immunotherapy in the future. Here, SEMA5B is linked to cancer.